3 active not recruiting, 2 recruiting, 1 enrolling by invitation. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Recruiting 2, Enrolling by invitation 1 |
Follow IMVT-1402: new trials by email Literature Review of IMVT-1402 trials Research Report on IMVT-1402
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) IMVT-1402 - Graves' Disease | Phase 2 | Enrolling by invitation | Immunovant Sciences GmbH | 372 | 2026-01-26 | 2026-09-29 |
| Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity IMVT-1402, Placebo - Primary Sjögren's Syndrome | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 180 | 2025-06-30 | 2026-09-10 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-10-30 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) IMVT-1402, Placebo - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 56 | 2025-02-19 | 2026-08-28 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis IMVT-1402, Placebo - Rheumatoid Arthritis | Phase 2 | Active not recruiting | Immunovant Sciences GmbH | 120 | 2025-01-10 | 2026-04-22 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
Graves Disease (3) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Hyperthyroidism (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Discoid (1)
Poland (6) · United Kingdom (6) · United States (6) · Georgia (5) · Spain (5) · Bulgaria (4) · Germany (4) · Hungary (4) · Argentina (3) · Chile (3) · Czechia (3) · Greece (3) · Italy (3) · Australia (2) · Canada (2)
2025 (2)